Lipid/Metabolic
Statins associated with increased progression of AMD, but caution is urged
May 1, 2008 | Charlotte Libov
From Medscape Medical News—a professional news service of WebMD

Ft Lauderdale, FL - A new study shows that the use of statins is associated with the progression of age-related macular degeneration (AMD), but the authors urge caution, saying that other causes may be the reason for the findings [1].

The authors presented the results of their study here at the Association for Research in Vision and Ophthalmology 2008 Annual Meeting.

"We are not saying that statins are a risk factor in the progression of age-related AMD. There are a lot of confounding variables. But what this study shows is that they don't seem to have a beneficial effect," lead author Dr Catherine Cukras (National Eye Institute, Bethesda, MD) said.

Using data from the Age-Related Eye Disease Study (AREDS), the researchers followed 1266 subjects for 11 years. The patients had neovascular AMD and/or central geographic atrophy (CGA).

The researchers found that 481 patients developed advanced AMD; among them, 323 eyes developed neovascular AMD and 233 developed CGA. Using multivariable analysis, they found that statin use was statistically significantly associated with the development of advanced AMD (odds ratio 1.43; 95% CI 1.12-1.83), but in analyses for types of advanced AMD, use of the drug was linked only with the development of neovascular AMD (odds ratio 1.76; 95% CI 1.34-2.30).

The researchers concluded that in AREDS, statin use was associated with patients developing advanced neurovascular AMD. However, previous studies have found an inconsistent association with cardiovascular risk factors, such as elevated cholesterol. Because statin use may be confounded by such conditions, no causal relationship should be drawn from this study's data. The study controlled for all AMD risk factors, including age, sex, education, smoking, body-mass index, hypertension, and antioxidant and zinc use.

Dr Frederick L Ferris III (National Eye Institute) pointed out,"We don't want patients to be concerned about the effects of statins on their eyes. [The drugs] have a beneficial effect on their life."

In an interview, Dr John T Thompson (University of Maryland, Baltimore) concurred: "The significance here is that there have been conflicting reports as to whether statins are protective, and this study says that they are not. There need to be further studies to sort this out."

The study did not receive commercial support. The authors and commentators have disclosed no relevant financial relationships.

The complete contents of Medscape Medical News, a professional news service of WebMD, can be found at www.medscape.com, a website for medical professionals.

Source
  1. Cukras CA, AgronE, SanGiovanni JP et al. The use of statins and the development of AMD in AREDS. Association for Research in Vision and Ophthalmology 2008 Annual Meeting; April 30, 2008; Ft Lauderdale, FL. Abstract 3772. Available here.




You have to be logged in to add a comment to this article
Login
Username 
Password 
  Forgot your password?
 
Remember me on this computer
 
Register
Click on "register" to create a account - It is free....
 
button
Previews
Featured CME
Inside: Lipid/Metabolic
Lipid/Metabolic
Jun 27, 2008 10:49 EDT
Ongoing interest exists in developing new pharmacologic approaches to address obesity and its sequelae of metabolic risk. Can intravascular ultrasound help us determine if we are on the right track to decreasing atherosclerotic progression with drug therapies? Join us for an insightful interview with Dr. Nissen on the STRADIVARIUS results, the benefits of IVUS and ongoing research examining CB1 blockade and its potential ability to decrease atherosclerotic progression by impacting more than just LDL reduction.
Lipid/Metabolic
Dec 18, 2007 13:39 EST
Drs Smith, Rader, Nesto, Plutzky, Nemeroff, and Pagotto explore the interrelated role of cardiometabolic risk factors and analyze the mechanism of action and evidence for the effectiveness of cannabinoid receptor type 1 (CB1) blockade in CVD.
Lipid/Metabolic
1 COMMENT - Jun 9, 2008 17:47 EDT
Join Drs Frank Sacks, Peter Jones and Theodore Mazzone as they discuss how the results of new clinical trials will affect the treatment of mixed dyslipidemia and reduce cardiovascular risk in patients with type 2 diabetes.
Lipid/Metabolic
47 COMMENTS - Mar 19, 2008 12:51 EDT
Join Drs Christie Ballantyne and Michael Davidson as they discuss the barriers to reaching target levels of all three key lipid components - LDL-C, HDL-C and triglycerides in the reduction of cardiovascular risk.
Lipid/Metabolic
May 30, 2008 15:55 EDT
Review data from recent trials on lipid-lowering agents, and evaluate this data within current lipid-lowering strategies to develop an evidence-based strategy for reducing CV risk in patients with hypercholesterolemia. Join Drs Davidson, Jones, and Radar.
Lipid/Metabolic
May 27, 2008 09:32 EDT
Drs Eckel, Libby, Musselman, Nesto and Nissen review evidence concerning the role of the endocannabinoid system (ECS) in cardiometabolic risk and its management. They also analyze emerging therapies for cardiometabolic risk and obesity, including compounds directed at the ECS.